LEADERSHIP

Dr. Chang Yi Wang, PhD

Founder and Chairperson

Dr. Wang is the founder of United Biomedical, Inc. and has served as the Chairperson of the Board of Directors since 1998, and as Chief Scientific Officer since December 1985. Dr. Wang is also Chairperson and Chief Executive Officer of UBI-Asia. The UBITh® platform technologies in both designer peptide based immunological applications and in protein and antibody drug development were developed under her direction. From 1981 to 1985, Dr. Wang was a principal investigator and head of the Laboratory of Molecular Immunology at the Memorial Sloan-Kettering Cancer Center in New York and a faculty member of the Department of Immunology, Sloan-Kettering Division, Cornell University Medical School. Dr. Wang received her B.S. degree in Chemistry from National Taiwan University and her Ph.D. degree in Immunology and Biochemistry from The Rockefeller University, New York. She is the principal inventor of over 80 of UBI’s issued patents and patent applications and has published more than 120 peer reviewed scientific papers. In 2007 Dr. Wang received the Inventor of the Year Award from the New York Intellectual Property Law Assocaition (NYPLA).

Mei Mei Hu, JD

Chief Executive Officer

Ms. Hu is the co-CEO of United Biomedical Inc., and a member of its Board of Directors. Ms. Hu was formerly a consultant at McKinsey & Co. in the New York office where she advised leading pharmaceutical and commodities companies on strategic, operational and management issues. While there, she was a firm expert on managing through economic cycles and developed a next generation risk assessment model for companies operating in cyclical industries. Prior to that, Ms. Hu was in the Securities group at Cravath, Swaine and Moore. Ms. Hu is also co-founder and partner at Jack Green Group, a consulting and investment firm, with completed transactions in biotechnology, solar, natural gas, and real estate. She received her B.A. degree in Economics from University of Pennsylvania, General Course certificate from London School of Economics, and her JD from Harvard Law School.

Dr. Ajay Verma, MD, PhD

Chief Medical Officer

Ajay Verma is a neurologist who is devoted to the advancement of neurotherapeutics and neurodiagnostics. He studied zoology at the University of Maryland and received his MD and his PhD in neurotoxicology from The Johns Hopkins University, training with Dr. Solomon Snyder. His neurology residency training was in the US Army at Walter Reed Army Medical Center, where he remained on clinical staff for another 11 years. Ajay spent 12 years on the faculty of the Uniformed Services University of the Health Sciences, the US Military’s Medical School. Since leaving the Army as a Lt. Colonel in 2006, Ajay has served in leadership roles at Merck & Co., Inc., Novartis Pharmaceuticals, and Biogen where he directed drug development, biomarkers, and experimental medicine efforts in Alzheimer’s and Parkinson’s disease, ALS, neuropathic pain, multiple sclerosis and other brain and neuromuscular disorders.

PJ Chen

VP of Global Clinical Development

PJ joined UNS in 2016. PJ has had a tremendous amount of experience in clinical development and CRO management. Prior to joining UNS, PJ served as head of North Asia at PPD and was responsible for business management and strategy. This included client, project and overall team management in the region with oversight of around 400 staff members. PJ also worked as head of project management and commercial operation for WuxiPRA, a joint venture CRO between WuXi AppTec and PRA Health Sciences. Before serving leadership roles in the CRO industry, PJ served as portfolio development lead at AstraZeneca and was responsible for the successful delivery of AZ development compounds. PJ received graduate training at Massachusetts Institute of Technology and conducted translational medicine research focused on imaging biomarkers at Martinos Center for Biomedical Imaging in Boston.

Martin Doran

VP of Finance

Martin, a Qualified Auditor and Chartered Accountant, joined UNS in 2016 with responsibility for financial & management reporting, budgeting and financial systems. Martin has worked over the last decade in strategic / management roles with various multinationals in the pharmaceutical & technology sectors (Pfizer Australia / Dublin, Oracle, Mylan). He has particular expertise in budgeting / control, commercial business partnering and implementing robust financial systems. He holds a BA in Accounting & HRM, Masters in Management Information Systems from University College Dublin and is a member of the Institute of Chartered Accountants of Ireland.

Dr. Chung-Ho Hung, PhD

VP of Product Development

Dr. Hung joined UBI in 2003 as the Vice President of Biological Product Development. Dr. Hung’s 20 plus years experience in the biotech industry is well-matched to UBI’s proprietary platform technologies. Dr. Hung’s experience encompasses biological product development, including purification of proteins and nature products, and their characterization for IND and PLA [or BLA] regulatory submissions to the FDA and the USDA, GMP manufacturing of biologicals including sterile injectables for immunoglobulin infusion, vaccine products, and blood screening diagnostics. Dr. Hung was previously Co-founder and Vice President of Research and Development of SumMax Corp. in Taiwan and the co-founder and vice president of research and development of Apollo Biomedicals Corp., Dr. Hung was Director of Protein Chemistry at Verigen and Director of Bioprocessing & Protein Chemistry and Senior Director of Research and Development. He is author of more than 27 publications and holds 6 patents. Dr. Hung received his BS degree in plant pathology from National Chung-Hsing University, Taiwan, his MS. in Veterinary Microbiology from Oklahoma State University, his Ph.D. in Biochemistry from the University of Kansas Medical Center.

Dr. Feng Lin, MD

New Vaccine Development Lead

Dr. Lin joined United Biomedical Inc., in 2005 as a research scientist. He is one of the key researchers in UBI for designing peptide immunogens. Prior to joining UBI, Dr. Lin practiced medicine as a chief resident and subsequently as chief physician at Beijing People’s Hospital, Beijing Medical School in 1983 and 1986. He became a faculty member in internal medicine at Beijing Medical School in 1985. In 1989, Dr. Lin was selected as an outstanding physician by the medical school for further training as a clinical fellow in Gastroenterology at Essen Medical School, West Germany. In 1990, Dr. Lin was invited as an exchange scholar to join a research team of Hepatology and Molecular Biology in Mount Sinai School of Medicine, New York, and subsequently, as a research scholar at Department of Medicine, College of Physicians and Surgeons, Columbia University. Dr. Lin has 13 scientific publications in prestigious scientific journals, with 6 being first author. Dr. Lin received his medical degree from Xian Medical School and did his internship at the Department of Infectious Diseases in Second Hospital of Xian Medical School.

H.E. Dr. Thomas Zeltner, MD, LLM

Chairman of the Advisory Board

Thomas Zeltner, MD, is an international expert leader in public health and health system development and former Secretary of Health of Switzerland and Federal Department of Home Affairs. He is a 2010 Fellow of the Advanced Leadership Initiative of Harvard University. He is co-founder of the Global Patient Safety Forum, a convening organization of the world’s leading patient safety organizations, and a Managing Editor of the Journal of Patient Safety. He advises international organizations and national governments in health policies and health policy reforms. He has served as Special Envoy in financing for WHO. In this capacity, he advised the Director General of WHO on the identification of an improved financing framework for the Organization. He is currently serving as Special Envoy of WHO, advising the Director General in critical areas of the current reform of this UN agency (how to cooperate with non-State actors such as NGOs and organizations in the private sector without compromising WHO’s integrity, and how to better align WHO’s priorities with the resources available to finance them). He is a member of the Global Agenda Council on Digital Health of the World Economic Forum (WEF).

Dr. Zeltner is president of Blood Transfusion CRS Switzerland, the organization in charge of securing Switzerland’s provision with blood and blood products. He is a board member of the Swiss Academies of Arts and Sciences and President of Science-et-Cite©. Since 1992, he has been Professor of Public Health at the University of Bern, Switzerland.

From 1991 to 2009, Dr. Zeltner was the Director-General of the Federal Office of Public Health of Switzerland, the National Health and Public Health Authority and Secretary of State for Health. In this function he was a key actor in Swiss health policy and represented Switzerland in many international health organizations.

He has served as the Assistant Editor for Global Programmes for the Journal of Patient Safety and is a subject matter expert on global public health issues for the Journal.

He was graduated with an MD and a master’s degree in law from the University of Bern. He holds a specialist degree in human pathology and forensic medicine.

Dr. Prof Kostas Lyketsos, MD

Advisor

Dr. Lyketsos was the founding director of the Johns Hopkins Neuropsychiatry Service, which he led for over a decade. He developed one of the largest and most successful academic neuropsychiatry programs in the USA with special expertise in dementia and traumatic brain injury. Prior to assuming leadership position at Johns Hopkins Bayview, he was and co-director of the Johns Hopkins Division of Geriatric Psychiatry and Neuropsychiatry. He has held a joint faculty appointment at the Hopkins Bloomberg School of Public Health since 1994. A world expert in the care and treatment of patients with Alzheimers and related dementias (AD), he has carried out pioneering work on the epidemiology and treatment of neuropsychiatric features of AD. His team is developing biomarkers to accelerate treatment development for AD and other forms of brain injury while designing and implementing innovative clinical trials. He leads efforts to ensure the provision of state of the art Dementia Care for people with dementia in the community. Dr. Lyketsos co-leads a Hopkins-wide effort to advance recovery of the wounded warrior and his family. He also serves on the NFL Players Association Mackey-White Mild Traumatic Brain Injury Committee for which he Chairs the Long-Term Outcomes subcommittee. In June 2010 he was Conference Chair of Traumatic Brain injury in Professional Football: An Evidence-Based Perspective sponsored by NFL.

Dr. Jeremy Friese, MD

Advisor

Dr. Friese is an interventional radiologist at Mayo Clinic in Rochester, Minnesota. His clinical and research focus includes minimally invasive vascular disease and cancer. He serves as Medical Director for New Ventures and Business Development in the Center for Individualized Medicine and as Associate Chair of Finance in the Department of Radiology. He is past chair of Novation’s imaging council and currently sits on the cardiovascular council. Dr. Friese is co-founder of Evidentia Health (a seed-stage HIT company), an active angel investor, and board member for SV Biosystems, Inc. He earned an M.D. from Mayo Medical School and an M.B.A. from Harvard Business School where he collaborated with Professors Clay Christensen and Michael Porter.

Dr. Dietrich Stephan, PhD

Advisor

Dietrich Stephan is the Chairman of the Department of the Department of Human Genetics at the University of Pittsburgh, and Associate Director of the Institute for Personalized Medicine of Pitt/UPMC where he leads the efforts in population genetics and translational acceleration. Prior to coming to Pittsburgh in 2013, he was founder, president and CEO of Silicon Valley Biosystems (SV Bio). SV Bio allows turnkey, accurate and comprehensive genetic testing for physicians to improve patient outcomes. Prior to founding SV Bio, Dr. Stephan was executive director of the Gene Partnership at Children’s Hospital Boston-Harvard Medical School – the nation’s No. 1-ranked pediatric hospital – where he worked to re-architect their care delivery model to bring modern genomic tools and strategies to bear to improve outcomes. In 2005, Dr. Stephan founded Navigenics Inc. Navigenics is recognized as having set the foundation for at-scale delivery of genome-based personalized medicine and shaping the regulatory and policy framework for this new field. Navigenics was acquired by Life Technologies in 2012. Prior to founding Navigenics, Dr. Stephan served on the leadership team at the Translational Genomics Research Institute (TGen). His roles at the institute were professor and chairman of the Neurogenomics Department and deputy director for Discovery Research of the institute overall, where he oversaw research and development. Dr. Stephan’s department was among the most productive neurological and mental health research groups in the world. He has founded several additional companies in the San Francisco Bay Area, including Aueon (cancer diagnostics), Amnestix (a pharmaceutical company developing cognitive enhancers acquired in 2007) and DiaVacs (an immunotherapy company focused on a cure for juvenile diabetes).

Dan Hunt, JD

Advisor

Daniel Hunt has 20 years of legal, IP, business development, transactional, alliance management, finance, and operational experience with prominent life science companies, including Genentech, Abgenix, Roche and Chiron. During his career he has acquired extensive experience integrating science, business legal disciplines in connection with life science transactions. Mr Hunt has led and closed hundreds of transactions with cumulative valuations in excess of $1B. He He is currently Legal counsel and head of alliance management for Comentis, Inc., Mr. Hunt was Associate General Counsel, Licensing, Contracts Management and Patent Law at Genentech, where he was responsible for managing Genentech’s business development and transactional activities in collaboration with Genentech’s business development, finance, research and alliance management groups, and was responsible for managing alliances for approved products and managing $2.5B in annual revenues from those alliances. Prior to Genentech, Mr. Hunt was the Director of Legal Affairs at Abgenix, where he was responsible for all company transactions, ranging from acquisitions and strategic collaborations to ordinary course transactions, and engaged in strategic planning for business development, product development, acquisition and manufacturing activities. At Roche Molecular Systems, Mr. Hunt was Chief Corporate Counsel. He was responsible for business development and transactional support and managed Roche’s PCR licensing program. Prior to Roche, Mr. Hunt was Senior Corporate Counsel at Chiron. Mr. Hunt began his career as a patent litigator and securities attorney at the law firm of Morrison & Foerster. Mr. Hunt obtained his law degree from the University of California at Berkeley, and his B.A. in Molecular Biology from the University of Colorado, Boulder.

Hans Von Celsing

Advisor

Mr. Hans Von Celsing serves as Business Advisor at NeuroVentures Capital LLC. Mr. Von Celsing serves as Executive Director of Business Development of Gelexir Healthcare Ltd. He served as Executive Vice President of Elekta Holdings U.S., Inc. and Elekta AB. He has 25 years of entrepreneurial, managerial and board experience from the Medical Technology Industry including spinal and neurosurgery. He serves as Director of Clinical Laserthermia Systems AB. He serves as a Director of Gelexir Healthcare Ltd. He graduated from Harvard Business School.

Dr. Campbell Murray, MD, MBA, MPH

Advisor

Dr. Campbell Murray is a Managing Director of Novartis Venture Fund in Cambridge, MA, USA. Prior to joining he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects. Campbell is a New Zealand-trained physician and worked as a Medical House Officer at Auckland Hospital. He is a Kauffman Fellow and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government, where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell serves on the boards of Aerpio, BioNano Genomics, Euthymics, Galera, ImaginAb and Neurovance.